Skip to content

Trial Summary

Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers

Acronym:

ASCOLT

ACTRN/NCT /ethics:

NCT00565708

Scientific title:

Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers

Summary:

We hypothesize through this randomized, placebo-controlled adjuvant study, that Aspirin in patients with dukes C or high risk dukes B colorectal cancer (ASCOLT) can improve survival in this patient population over placebo control. If indeed found to be beneficial, because aspirin is cheap and easy to administer, it will positively impact the lives of many individuals in Asia and globally.

Trial & Patient Characteristics

Cancer TypeBowel
Trial TypeTreatment
PhasePhase III
Age Range18+ years
SexBoth
Tumour StreamBowel
Cancer StageAll stages
Anticipated Start Date2018-12-01
Anticipated End Date-

Participating Hospitals

HospitalLyell McEwin Hospital
Clinical Trial CoordinatorAndy Phay
Emailandy.phay@sa.gov.au
Phone08 8282 0833
Principal InvestigatorProfessor Tim Price
Recruitment StatusRecruiting